Healthcare M&A Trends 2026: Where Capital Is Moving and What’s Selling

Key Takeaways

• FTC scrutiny and state AG actions in 2024 and 2025 fundamentally changed the calculus for physician practice rollups, slowing the pace of platform consolidation
• Behavioral health is the standout growth sub-sector in 2026, with multiples sustained at 12 to 18x EBITDA on platforms with scaled clinical operations
• Dental DSOs are entering a maturity wave with consolidation among existing platforms rather than new platform creation, producing 8 to 14x multiples on quality assets
• Search funders and family offices have replaced first-wave PE as the marginal buyer in many sub-sectors at the $3M to $25M EBITDA range
• California SB 1120, New York Article 28, and Texas Medical Practice Act developments have created state-by-state regulatory geography sellers must understand
• Sellers in 2026 should expect to roll 20 to 40 percent equity, accept longer earn-outs, and budget for regulatory escrow holdbacks that did not exist in 2022 deals

The 2024-2025 reset: why physician rollups stalled

Healthcare M&A in 2026 is operating in a different regulatory environment than 2022. The 2024 and 2025 period saw significant antitrust attention to physician practice consolidation, state-level corporate practice of medicine enforcement, and federal scrutiny of MSO structures that PE firms had used as the standard rollup vehicle.

The result was a measurable pullback in physician practice rollup activity in 2025. Several large PE firms announced they were pausing new platform investments in physician specialties, refocusing on operational improvement of existing platforms, and shifting acquisition capital toward sub-sectors with less regulatory friction.

The pullback was not universal. Some physician specialties continued to attract capital because of specific structural advantages (ancillary revenue streams, defensible referral patterns, technology-enabled service models). Other specialties saw multiples compress significantly as buyer interest waned.

For sellers, the implication was sub-sector specific. A dermatology practice owner in 2026 faced a very different market than the 2022 peak. An MSK or orthopedic practice owner faced a relatively healthy market. A behavioral health platform faced premium multiples. The blanket statement that healthcare M&A is hot or cold no longer applied.

The 2024-2025 reset also changed the buyer mix. First-wave PE firms with mandates focused on physician rollups either paused or pivoted. Their successors in the market include strategic operators (existing healthcare platforms growing via tuck-ins rather than new platform creation), search funders looking for single-practice or small-platform acquisitions outside the regulatory hot zones, and family offices doing direct healthcare investments with longer hold periods.

The implications for sellers in 2026 are concrete. Sellers should expect: longer diligence timelines because buyers are more careful about regulatory risk, more complex deal structures that allocate regulatory risk between buyer and seller, smaller buyer pools in the most-affected sub-sectors, and rigorous attention to MSO structure and corporate practice of medicine compliance.

For broader M&A context, see the sell-side M&A process and how service businesses get acquired by PE.

The FTC focus on healthcare consolidation

The Federal Trade Commission shifted its enforcement focus toward healthcare consolidation starting in 2022 and accelerating through 2024 and 2025. The agency challenged several anesthesia and emergency medicine rollups, opened inquiries into specialty rollups in dermatology, gastroenterology, and ophthalmology, and signaled that the rollup model itself was under scrutiny rather than just specific transactions.

The mechanism was the noncompete enforcement question, the question of whether series of small acquisitions added up to anticompetitive scale, and the question of whether management services organization (MSO) structures were genuinely arms-length or were effective control by the PE owner. Each question raised regulatory risk for buyers and sellers in physician practice deals.

State attorney general activity

State AGs took separate actions in 2024 and 2025 that complicated the regulatory geography. California, New York, Oregon, Connecticut, and Massachusetts all initiated review processes for healthcare transactions, with material transactions in these states now subject to AG notice and review. The review timelines added 60 to 180 days to closings and produced unpredictable outcomes.

The state activity matters because healthcare deals are often multi-state by structure. A platform with practices in five states may need to work through five separate regulatory regimes, with each state potentially blocking or modifying the transaction. The cost of regulatory work increased and the certainty of close decreased.

Where capital is flowing in 2026: the active sub-sectors

Despite the overall slowdown in physician rollups, capital continued to flow into specific healthcare sub-sectors throughout 2025 and into 2026. The sub-sectors share common characteristics: demographic tailwinds, scalable clinical operations, defensible ancillary revenue, and limited regulatory exposure compared to the most-affected specialties.

1. Behavioral health

Behavioral health is the standout sub-sector in 2026. Capital flow has accelerated, multiples have held at premium levels, and the buyer pool has expanded to include healthcare specialty PE, generalist PE, family offices, and strategic operators. Mental health platforms operating outpatient services (therapy, psychiatry, medication management) trade at 12 to 18x EBITDA on quality assets with scaled operations.

The drivers are demographic (post-pandemic demand surge that has not abated), structural (most patients are insurance-paid with reliable payer mix), and operational (technology-enabled service delivery, telehealth integration, and standardized clinical operations). Substance use disorder platforms (SUD, MAT, recovery) trade slightly lower but still in the 10 to 14x range on quality assets.

2. Fertility and IVF

Fertility and IVF practices continue to attract premium multiples in 2026, typically 10 to 16x EBITDA on platforms with multiple physicians and operational scale. The drivers are cash-pay economics (most IVF is patient-paid, removing payer risk), strong demand growth, and proven consolidation models. Several large fertility platforms have continued aggressive add-on acquisition through 2025 and 2026.

3. Dermatology re-entry

Dermatology M&A had a peak in 2020-2022, a significant pullback in 2023-2024 as multiples compressed and regulatory attention focused on the sub-sector, and a measured re-entry in 2025-2026. New platforms are forming with focus on quality of clinical operations and ancillary revenue (cosmetic dermatology, dispensary, skin cancer surgery). Multiples in 2026 typically run 9 to 13x EBITDA, down from the 13 to 16x peak.

4. Urgent care consolidation

Urgent care consolidation continues in 2026, often through strategic acquirers (hospital systems, large urgent care platforms) and ETA platform-add-on deals. Multiples range 8 to 12x EBITDA on multi-site platforms, with single-site deals at lower multiples. Real estate ownership at urgent care sites can produce significant additional value beyond the operating multiple.

5. MSK and orthopedics

Musculoskeletal and orthopedic practices are an active 2026 sub-sector because of surgical revenue, ancillary revenue (imaging, physical therapy, ASC ownership), and demographic tailwinds. Multiples run 8 to 12x EBITDA on quality platforms, with surgery center ownership adding incremental value. The sub-sector has avoided the worst of the FTC scrutiny because of strong professional independence and surgical economics.

6. Home health

Home health and home-based care continue to attract capital in 2026 because of demographic demand, Medicare reimbursement support, and operational scalability. Multiples run 8 to 12x EBITDA on quality home health platforms, with hospice and home-based primary care attracting premium multiples in the 10 to 14x range.

7. Dental DSO maturity wave

Dental DSOs are entering a maturity wave in 2026. The first wave of DSO platform creation peaked in 2021-2022 with multiples reaching 14 to 18x EBITDA. The 2023-2024 correction brought multiples down to 6 to 9x as several platforms struggled with same-store performance and integration. The 2026 environment is consolidation among existing platforms with multiples in the 8 to 14x range for quality assets.

The DSO buyers in 2026 are existing scaled platforms acquiring tuck-ins, secondary PE buyers acquiring portfolios from first-wave PE, and selective new platform entrants in attractive geographies. Solo and small-group dental practices face a different market: lower buyer interest, more careful diligence, and tighter terms than 2021.

For service-business buyer patterns more broadly, see service business PE acquisition playbook.

Why these sub-sectors stayed active

Each active sub-sector shares structural characteristics that kept capital flowing through the 2024-2025 reset. Behavioral health has demographic tailwinds (rising demand) and scalable clinical operations. Fertility has strong cash-pay economics and demographic demand. Dermatology has ancillary revenue streams (cosmetic, dispensary) that complement medical practice. Urgent care has real estate plays and consumer-direct models. MSK has surgical and ancillary revenue. Home health has reimbursement and demographic tailwinds. Dental DSOs have scaled operating models that proved through prior cycles.

The sub-sectors that stalled (anesthesia, emergency medicine, primary care platforms) shared the opposite characteristics: pure professional fee economics, high noncompete exposure, weak ancillary revenue, and direct collision with the FTC scrutiny focus.

The geography of capital flow

Capital flow is not just sub-sector specific in 2026; it is also geographically specific. Florida, Texas, Arizona, Tennessee, and the Carolinas remain active for healthcare deals because of demographic growth, regulatory clarity, and existing platform concentration. California, New York, Oregon, and Connecticut face more regulatory friction and have seen capital pull back somewhat.

Sellers in friendly geographies typically see higher multiples and stronger buyer interest. Sellers in friction geographies should expect to demonstrate strong corporate practice of medicine compliance, transparent MSO structures, and willingness to extend regulatory escrows. Geographic factors alone can move multiples by 1 to 2 turns of EBITDA on the same business.

Multiples by sub-sector: the 2026 ranges

Sub-sector multiples in 2026 reflect the post-reset environment: compression from 2021-2022 peaks, dispersion based on quality and geography, and premium maintained in sub-sectors with structural advantages.

Behavioral health: 12 to 18x EBITDA for quality outpatient mental health platforms with scaled operations ($5M+ EBITDA, multi-site, institutional management). Substance use platforms run 10 to 14x. Smaller behavioral health practices ($1M to $5M EBITDA) trade at 8 to 12x.

Fertility and IVF: 10 to 16x EBITDA for multi-physician fertility platforms with operational scale. Smaller single-physician practices trade at 6 to 10x because of physician concentration risk.

Dermatology: 9 to 13x EBITDA for platforms with diverse revenue (medical, surgical, cosmetic, dispensary) and institutional management. Solo dermatology practices trade at 5 to 9x with significant variation based on payer mix and geographic factors.

Urgent care: 8 to 12x EBITDA for multi-site urgent care platforms. Single-site urgent care trades at 5 to 8x. Hospital-system-attached urgent care valuations follow strategic acquisition logic rather than pure financial multiples.

MSK and orthopedics: 8 to 12x EBITDA on multi-physician orthopedic platforms with surgical revenue, ancillary services, and ASC ownership. ASCs themselves trade at separate multiples (7 to 11x for ortho-focused ASCs). Single-surgeon practices trade at 4 to 7x.

Home health: 8 to 12x EBITDA on multi-location home health platforms with quality clinical operations and stable Medicare reimbursement. Hospice platforms run 10 to 14x because of the typically higher EBITDA margins and predictable reimbursement. Home-based primary care trades at 10 to 16x because of demographic tailwinds and value-based care orientation.

Dental DSOs: 8 to 14x EBITDA for quality DSO platforms with multi-site scale, institutional management, and same-store growth. The range reflects the post-2023 correction; pre-correction peaks ran 14 to 18x. Smaller dental groups (3 to 10 locations) trade at 5 to 9x.

Anesthesia, emergency medicine, primary care platforms (the sub-sectors most affected by 2024-2025 regulatory scrutiny): multiples compressed materially. Anesthesia platforms that traded at 12 to 16x in 2021 now trade at 7 to 11x. Emergency medicine staffing platforms struggle with deal flow at all. Primary care platforms vary significantly based on value-based care contracting, with VBC-oriented primary care at 10 to 16x and traditional FFS primary care at 6 to 9x.

Gastroenterology, ophthalmology, ENT: post-2024 multiples typically 8 to 12x for quality platforms, down from 12 to 15x at the peak. The buyer pools are smaller but still active for quality assets in attractive geographies.

Veterinary (often included in healthcare M&A discussions): vet platforms trade at 12 to 18x for quality multi-site groups, holding closer to peak levels than human healthcare because of less regulatory exposure. Single-doctor vet practices trade at 5 to 9x.

For more on how multiples translate to deal economics, see PE vs strategic buyer.

What drives multiple variation within a sub-sector

Within any sub-sector, multiples vary significantly based on scale (larger platforms trade at higher multiples than small practices), growth rate (organic same-store growth premium of 1 to 3 turns), profitability (EBITDA margin above sub-sector median earns premium), management depth (institutional management commands premium over founder-dependent), and ancillary revenue (defensible ancillary streams add 1 to 2 turns).

The published ranges below represent typical deal pricing, not extremes. Quality assets in attractive geographies with institutional management can exceed the top of the range; founder-dependent small practices with operational issues trade below the bottom of the range.

Where the data comes from

The 2026 multiple ranges below synthesize information from PitchBook healthcare deals databases, Capstone Partners and Provident healthcare M&A reports, Bain healthcare PE annual report, broker and advisor transaction logs, and direct deal observations from active 2025-2026 transactions. Specific deal multiples vary widely; the ranges represent typical pricing for quality assets in active sub-sectors.

Sellers should validate sub-sector pricing with their advisor’s recent transaction data and the published industry research available through their advisor or independently. The ranges shift quarterly as market conditions evolve.

The new buyer mix in 2026

The healthcare buyer pool in 2026 looks structurally different from the 2020-2022 peak. First-wave PE firms have pulled back from new platform creation. Search funders, family offices, and strategic operators have moved in to fill the gap. The marginal buyer at any given deal size is often not the same buyer who would have been there three years ago.

Buyer type 1: Healthcare specialty PE

Specialty PE firms with healthcare-only mandates (Welsh Carson, TPG Healthcare, GTCR healthcare practice, Riverside, others) continue to be active in 2026 but more selectively than in 2021. Their focus is on quality platforms in attractive sub-sectors (behavioral health, fertility, MSK, home health), often through add-on acquisition to existing platforms rather than new platform creation.

Buyer type 2: Generalist PE with healthcare expertise

Large generalist PE firms (KKR, Bain Capital, Apollo, Carlyle, others) have healthcare practices that remain active in 2026, often focused on larger platform deals ($25M+ EBITDA) where the regulatory complexity is manageable through dedicated legal and compliance resources.

Buyer type 3: Family offices doing direct healthcare investments

Family offices have moved more aggressively into direct healthcare investments in 2024-2026, often partnering with operator-CEOs or buying out PE-owned platforms in secondary transactions. Family office buyers typically offer longer hold periods (10+ years vs PE’s 4 to 7 year hold), less aggressive growth targets, and willingness to maintain founder involvement in some structures.

Buyer type 4: Search funders

Search funders (typically MBA-trained operators raising small fund commitments to acquire and run a single business) have become significant buyers at the $3M to $15M EBITDA range in 2026. Their model fits healthcare practices where operator focus and longer hold periods produce better outcomes than rollup-driven scale.

Buyer type 5: Strategic operators expanding via tuck-ins

Strategic operators (large existing healthcare platforms, regional health systems, vertically integrated companies) have expanded their acquisition activity in 2025-2026 as PE pulled back. Their offers typically include synergy assumptions (cost savings, revenue uplift, cross-selling) and may pay higher multiples than financial buyers for the right strategic fit.

Buyer type 6: ETA platform-add-on increasing share

The Entrepreneurship Through Acquisition (ETA) community, including both traditional search funders and self-funded ETA buyers, has continued to grow as a buyer category for smaller healthcare practices and platforms. Recent ETA acquisitions have included urgent care groups, behavioral health practices, dental offices, and home health agencies in the $1M to $10M EBITDA range.

For sellers in 2026, the implication is that buyer fit matters more than it did in 2021. The right buyer for a particular practice may not be a financial buyer at all – it may be a strategic operator, a search funder, or a family office. Engaging an advisor who can run a process across multiple buyer types becomes more valuable when the buyer mix is more diverse.

For more on search fund buyers specifically, see search fund acquisition explained.

Why first-wave PE pulled back

First-wave healthcare PE firms (those that built platforms in 2014-2022) faced several headwinds simultaneously in 2024-2025: regulatory scrutiny on the rollup model, integration challenges at existing platforms, weaker same-store growth than projected, and difficulty deploying capital at attractive multiples. Many firms paused new platform investments and focused on operational improvement of existing portfolios.

The pullback was not abandonment. First-wave PE firms continued operating their existing platforms, continued executing tuck-in acquisitions within existing platforms, and continued exit activity through secondary sales to larger PE firms or strategic acquirers. New platform creation is what slowed, not all PE activity.

How search funders changed the small-platform market

Search funders raised significant capital in 2023-2025 specifically targeting healthcare acquisitions in the $5M to $25M EBITDA range. The search fund model (single operator acquires single business, runs it for 5 to 10 years, then exits) fits well with healthcare practices that benefit from operator focus rather than rollup synergies.

Search funders typically pay full-market multiples but offer sellers different deal characteristics than PE: longer hold periods, operator continuity, ESOP-like outcomes for management teams in some cases, and lower regulatory complexity than multi-state PE platforms. For sellers prioritizing legacy and continuity, search funders became an attractive alternative in 2026.

State-by-state regulatory headwinds

Healthcare M&A in 2026 operates within a state-by-state regulatory geography that did not exist in this form three years ago. Several states have enacted or strengthened healthcare transaction review processes, corporate practice of medicine enforcement, and certificate of need (CON) requirements.

California: SB 1120 effective 2024 plus ongoing state Attorney General review of healthcare transactions creates the most demanding regulatory environment in the country for healthcare deals. Material transactions involving California-based providers face mandatory state review with timelines of 60 to 180 days and the possibility of conditions or rejection.

New York: Article 28 framework regulates many healthcare facilities, with certificate of need (CON) approval required for certain ownership changes. New York Department of Health review timelines extended in 2024-2025 to 6 to 12 months for some transactions. New York City adds municipal review layers.

Oregon: Senate Bill 870 (effective 2024) requires advance notice and review of material healthcare transactions, with the Oregon Health Authority having authority to delay or block transactions that raise competitive or quality concerns. Review timelines typically run 90 to 180 days.

Connecticut: Public Act 22-19 (effective 2023) created a Health Care Cost and Quality Council with review authority over healthcare transactions. Review processes have evolved through 2024-2025 with continuing implementation.

Massachusetts: Strengthened oversight through the Massachusetts Health Policy Commission and AG review processes for material healthcare transactions. Massachusetts deals typically include regulatory escrows and longer post-LOI timelines.

Texas Medical Practice Act: Texas has not added new transaction review requirements in 2024-2026, but the existing corporate practice of medicine framework remains strict. PE-backed deals in Texas require careful MSO structuring and physician-controlled professional entities. Texas remains an attractive geography for healthcare deals because of clearer rules and demographic growth.

Florida: Limited state transaction review requirements make Florida a relatively friendly geography for healthcare M&A in 2026. Florida deals close faster than equivalent California or New York deals. Florida demographics also support healthcare demand growth.

Tennessee, Arizona, Carolinas, Georgia: These states have remained relatively friendly to healthcare M&A through 2024-2026, with reasonable regulatory frameworks and growing markets. Many healthcare platforms have concentrated geographic growth in these states partly because of the regulatory clarity.

For sellers, the geographic implications are direct: practices in friendly geographies typically sell faster, at higher multiples, and with simpler deal structures than equivalent practices in friction geographies. Multi-state platforms face higher regulatory costs that affect both deal pricing and certainty of close.

The regulatory geography is evolving. Sellers should engage healthcare-experienced counsel early in any sale process to understand the specific state-level implications of their transaction.

California: SB 1120 and corporate practice scrutiny

California Senate Bill 1120 (effective 2024) and subsequent state activity have heightened scrutiny on physician group structures, MSO arrangements, and PE ownership of healthcare entities. The California Attorney General’s office reviews material healthcare transactions, with timeline impacts of 60 to 180 days and the possibility of conditions or rejections.

California healthcare deals in 2026 require careful structuring around the corporate practice of medicine doctrine, transparent MSO documentation, and willingness to engage with AG review processes. Multi-state platforms with California operations face additional complexity. Some buyers have explicitly excluded California from their geographic focus because of the regulatory burden.

New York Article 28 and certificate of need

New York’s Article 28 framework regulates many healthcare entities and requires certificate of need (CON) approval for certain ownership changes and facility expansions. The New York Department of Health review timelines have extended in 2024-2025, with deal closings sometimes delayed 6 to 12 months for CON reviews.

New York healthcare deals require early engagement with the regulatory process, clear documentation of clinical operations, and contingency planning for review timeline uncertainty. Deals in New York City face additional state and city level review processes that further extend timelines.

Deal structures in 2026: what is different from 2022

Deal structures in 2026 healthcare M&A look meaningfully different from the 2022 environment. The structural changes reflect buyer caution after the 2024-2025 regulatory reset, longer hold periods at PE platforms, and lessons learned from earlier transactions that produced disputes or under-performance.

Change 1: Larger rollover equity requirements

2022: rollover equity in healthcare deals typically 10 to 20 percent of consideration, sometimes structured as preferred or as common with put rights.

2026: rollover equity typically 20 to 40 percent, structured as common equity with no put rights, valued at the deal multiple at close. The seller’s economic outcome depends heavily on the platform’s exit multiple 4 to 7 years later. Sellers should model rollover scenarios carefully and understand the buyer’s expected hold period and exit strategy.

Change 2: Longer earn-outs

2022: earn-outs typically 2 to 3 year periods with EBITDA-based or revenue-based triggers.

2026: earn-outs typically 3 to 5 year periods with more conservative triggers (often tied to EBITDA growth above a high baseline). Earn-out collection rates in 2024-2025 disappointed many sellers, leading sellers to negotiate harder on terms and to discount earn-out value in their net proceeds modeling.

Change 3: Management incentive plans (MIPs)

2022: MIPs typically grant 5 to 10 percent of equity to management team over 4 to 5 year vesting periods.

2026: MIPs frequently grant 10 to 15 percent of equity to management team, often with performance-based vesting (vest on EBITDA growth, revenue growth, or other operating milestones). The larger MIPs reflect buyer recognition that management continuity is more important than 2022 deals assumed.

Change 4: Regulatory escrow holdbacks

2022: standard escrow of 5 to 10 percent for general indemnification, sometimes a small holdback for specific regulatory items.

2026: separate regulatory escrow of 2 to 8 percent of deal value, held 18 to 36 months, dedicated to pre-close regulatory issues that may surface after closing. This is in addition to general indemnification escrow. Some deals have both indemnification escrow and regulatory escrow totaling 10 to 15 percent of deal value held for extended periods.

Change 5: Stronger restrictive covenants

2022: non-compete restrictions typically 2 to 3 years post-close, geographic scope sometimes national.

2026: non-compete and non-solicit restrictions remain comparable in scope but with more careful drafting given FTC noncompete enforcement scrutiny. Some deals replace traditional non-competes with garden leave provisions, deferred compensation structures, or non-solicit-only restrictions. The legal landscape on noncompetes continues evolving and deal terms reflect the uncertainty.

Change 6: Working capital methodology

2022: working capital targets often set at trailing-twelve-month average with simple true-up.

2026: working capital methodology more carefully negotiated, with specific definitions of current assets and current liabilities, seasonal adjustments, peg-setting methodologies, and detailed true-up procedures. The post-close working capital adjustment process has become one of the more contested areas of healthcare deals.

Change 7: Quality of earnings rigor

2022: quality of earnings analysis common but sometimes treated as a checkbox diligence item.

2026: quality of earnings analysis is rigorous, with buyers often commissioning extensive sell-side QofE before the deal launches and detailed buy-side QofE during diligence. Sellers should expect detailed scrutiny of revenue recognition, contractual adjustments, payer mix, and same-store growth methodology.

Change 8: Representation and warranty insurance

2022: RWI common on larger healthcare deals to provide post-close indemnification protection.

2026: RWI still common but with more careful underwriting and pricing reflecting healthcare-specific risks. Premiums have increased somewhat and exclusions for specific risks (regulatory matters, billing compliance) are more carefully defined.

Why rollover equity expanded

Rollover equity (where the seller takes a portion of consideration as ownership in the new entity rather than cash at close) became more common and larger in healthcare deals in 2024-2026. Several drivers: buyers want sellers economically aligned with future performance, regulatory uncertainty makes buyers want shared risk, and PE returns assumptions require continued seller engagement post-close.

The typical rollover in 2026 healthcare deals is 20 to 40 percent of consideration. Sellers receive 60 to 80 percent in cash at close and roll the balance into the new entity, which they typically hold until the buyer’s exit event (usually 4 to 7 years later). The rollover value depends on the entity’s performance and exit multiple, creating significant upside potential but also downside risk.

Regulatory escrows as a new line item

Regulatory escrows became standard in healthcare deals in 2024-2026, sized at 2 to 8 percent of deal value, held for 18 to 36 months post-close. The escrow protects buyers against pre-close regulatory issues that surface after closing (billing compliance, corporate practice issues, license matters).

Sellers should expect to negotiate the escrow size, holding period, release schedule, and dispute resolution mechanics. A regulatory escrow that releases on a fixed schedule with limited buyer claims rights is significantly more seller-friendly than one held indefinitely with broad buyer claims rights. The legal negotiation around regulatory escrows has become one of the more complex parts of healthcare deals.

What sellers should do differently in 2026 vs 2022

Sellers preparing for healthcare M&A in 2026 face a different market than 2022 sellers did. The actions that produced strong outcomes in 2022 are not the same as the actions that produce strong outcomes in 2026. Several specific adjustments make a meaningful difference.

Adjustment 1: Invest more in pre-launch preparation

2022 sellers often launched within 60 to 90 days of deciding to sell. 2026 sellers should plan 6 to 12 months of pre-launch preparation including quality of earnings work, regulatory compliance audit, MSO structure review, financial cleanup, and customer/patient concentration analysis. The preparation produces cleaner diligence and stronger positioning.

Adjustment 2: Engage healthcare-specialty advisors and counsel

Generalist M&A advisors and attorneys handled most 2022 deals adequately. 2026 deals require healthcare-specific expertise on regulatory matters, MSO structuring, corporate practice compliance, and billing/coding diligence. Engage advisors and counsel who specialize in healthcare M&A in your sub-sector and geography.

Adjustment 3: Plan for longer process timelines

2022 healthcare deals often closed in 4 to 6 months from launch. 2026 healthcare deals typically take 6 to 12 months because of more careful diligence, regulatory review timelines, and complex deal structuring. Sellers should plan personal and operational timelines around the longer process.

Adjustment 4: Model the full deal economics, not just the headline price

2022 sellers often focused heavily on enterprise value and EBITDA multiple. 2026 deals require modeling of cash at close (after working capital adjustment, escrow, transaction expenses), rollover equity value (with scenario analysis on exit multiples), earn-out probability and present value, regulatory escrow timing and release probability, and management incentive plan dilution. The headline number can mask significant variation in actual net proceeds.

Adjustment 5: Run broader buyer processes

2022 healthcare processes often targeted financial buyers (PE) primarily. 2026 processes should include strategic operators, family offices, search funders, and potentially ESOPs in the buyer pool. The expanded buyer mix produces better optionality and pricing pressure. Engaging an advisor who can run multi-buyer-type processes becomes more important.

Adjustment 6: Negotiate regulatory escrows carefully

Regulatory escrows are nearly universal in 2026 healthcare deals. Sellers should negotiate size (target 2 to 5 percent rather than buyer’s typical opening of 5 to 10 percent), holding period (target 18 to 24 months rather than 36+ months), release schedule (target fixed releases at intervals), and dispute resolution mechanics (target arbitration with seller-friendly forum selection).

Adjustment 7: Plan post-close transition carefully

2022 deals often involved limited seller continuity post-close. 2026 deals typically require 6 to 24 months of seller involvement, often with rollover equity providing ongoing economic alignment. Sellers should plan personal timelines, retirement transitions, and post-close roles before the deal launches rather than negotiating these at the last minute.

Adjustment 8: Document everything

2022 deals tolerated some informal documentation around clinical operations, payer contracts, and management practices. 2026 deals require comprehensive documentation: detailed clinical protocols, payer contract registries, billing compliance documentation, MSO documentation, corporate practice compliance evidence, and employee/contractor structures. Pre-launch documentation work is essential.

For broader pre-sale framework, see the sell-side M&A process.

Pre-launch preparation work

Sellers in 2026 should invest more in pre-launch preparation than 2022 sellers typically did. Specific recommended work: sell-side quality of earnings (3 to 6 months before launch, cost $25K to $75K), legal diligence preparation including MSO structure review and corporate practice compliance audit, regulatory compliance audit covering billing, coding, licensing, and any pending matters, and customer/patient concentration analysis with documented retention metrics.

The investment in pre-launch preparation pays back through cleaner diligence processes, faster closings, and reduced risk of retrading. Sellers who skip this preparation increasingly find their deals delayed or repriced when buyer diligence surfaces issues that pre-launch preparation would have addressed.

Process design choices

Sellers in 2026 should consider running broader processes than 2022 sellers typically did because the buyer mix is more diverse. A 2022 healthcare sell-side might have targeted 20 to 40 PE firms. A 2026 sell-side should target a broader mix: PE firms, family offices, search funders, strategic operators, and potentially ESOP buyers. The expanded process produces better optionality and stronger pricing pressure.

The expanded process also costs more in advisor fees and takes longer to run. Sellers should budget for advisor retainers covering 6 to 14 months of process and expect total advisor costs of 4 to 8 percent of deal value (retainer plus success fee) on lower middle market healthcare deals.

Frequently Asked Questions

What are the biggest healthcare M&A trends in 2026?

The dominant trends are: PE pullback from physician practice rollups after 2024-2025 antitrust scrutiny, capital concentration in behavioral health, fertility, dermatology re-entry, MSK, home health, and dental DSO consolidation, a more diverse buyer mix with search funders and family offices replacing first-wave PE, larger rollover equity requirements (20 to 40 percent), and state-by-state regulatory geography that varies widely from friendly states like Texas and Florida to friction states like California and New York.

Why did PE pull back from physician practice rollups?

The 2024-2025 period saw FTC enforcement focus on healthcare consolidation, state Attorney General review of healthcare transactions, and scrutiny of MSO structures that PE firms used as the standard rollup vehicle. Several high-profile transactions were challenged or modified by regulators. First-wave PE firms responded by pausing new platform investments in physician specialties and focusing on operational improvement of existing portfolios.

Which healthcare sub-sectors have the highest multiples in 2026?

Behavioral health leads with 12 to 18x EBITDA on quality outpatient mental health platforms. Fertility and IVF runs 10 to 16x. Hospice and home-based primary care run 10 to 14x. Veterinary platforms run 12 to 18x. Other active sub-sectors (dermatology, MSK, urgent care, home health, dental DSO) typically run 8 to 13x EBITDA on quality assets with institutional management.

How have dental DSO multiples changed in 2026?

Dental DSOs entered a maturity wave in 2026. The 2021-2022 peak saw multiples at 14 to 18x EBITDA on quality platforms. The 2023-2024 correction brought multiples down to 6 to 9x as several platforms struggled. The 2026 environment has multiples at 8 to 14x for quality assets, with consolidation occurring among existing platforms rather than significant new platform creation. Smaller dental groups trade at 5 to 9x.

Who are the active buyers in healthcare M&A in 2026?

Six buyer categories are active: healthcare specialty PE firms (Welsh Carson, TPG Healthcare, Riverside, others) focusing on quality platforms, generalist PE on larger deals, family offices doing direct healthcare investments with longer hold periods, search funders at the $3M to $15M EBITDA range, strategic operators expanding via tuck-ins to existing platforms, and ETA buyers (search funders and self-funded ETA operators) at smaller deal sizes.

Which states have the most demanding healthcare M&A regulatory environments?

California (SB 1120 and ongoing AG review), New York (Article 28 and certificate of need), Oregon (SB 870), Connecticut (Public Act 22-19), and Massachusetts (Health Policy Commission oversight) have the most demanding healthcare transaction review processes. Review timelines run 60 to 180 days or longer. Texas, Florida, Tennessee, Arizona, and the Carolinas have more streamlined regulatory environments and are favored geographies for healthcare M&A.

How much rollover equity should I expect in a 2026 healthcare deal?

2026 healthcare deals typically require sellers to roll 20 to 40 percent of consideration into rollover equity, compared to 10 to 20 percent in 2022 deals. The rollover is held until the buyer’s exit event, typically 4 to 7 years later, with the value depending on platform performance and exit multiple. Sellers should model rollover scenarios carefully and understand the buyer’s expected hold period and exit strategy.

What is a regulatory escrow in healthcare M&A?

A regulatory escrow is a holdback (typically 2 to 8 percent of deal value) held for 18 to 36 months post-close to protect the buyer against pre-close regulatory issues that surface after closing. Common issues covered include billing compliance, corporate practice of medicine violations, license matters, and pending regulatory investigations. Regulatory escrows are largely new in 2024-2026 deals and are in addition to general indemnification escrow.

How long does a healthcare M&A deal typically take in 2026?

2026 healthcare deals typically run 6 to 12 months from launch to close, longer than the 4 to 6 months typical in 2022. The extended timeline reflects more careful diligence, state regulatory review timelines (60 to 180 days in friction states), rigorous quality of earnings work, and more complex deal structuring. Sellers should plan personal and operational timelines around the longer process.

What should I do differently if I’m selling a healthcare business in 2026?

Eight specific adjustments: invest 6 to 12 months in pre-launch preparation including sell-side QofE, engage healthcare-specialty advisors and counsel, plan for longer process timelines, model full deal economics not just headline price, run broader buyer processes including search funders and family offices, negotiate regulatory escrows carefully, plan post-close transition before launch, and document everything comprehensively. The pre-launch work materially affects deal outcomes in 2026.